Abstracts tagged "Biologicals"

Abstract Number: 0351 • ACR Convergence 2020
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Laure Gossec¹, Elke Theander², Soumya Chakravarty³, Paul Bergmans⁴, Iris Lin⁵, Wim Noël⁶, Stefan Siebert⁷ and Josef Smolen⁸, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Janssen Cilag, Lund, Sweden, ³Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁴Janssen Biostatistics and Medical Affairs, Tilburg, Netherlands, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Medical Affairs, LLC, Beerse, Belgium, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…
Abstract Number: 0478 • ACR Convergence 2020
Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program
Sirisha Gokaraju¹, Angus Worthing², Katherine Maher³, Grace Wright⁴ and Gail Kerr⁵, ¹Georgetown University hospital, Bethesda, MD, ²Arthritis & Rheumatism Associates, PC, Washington, DC, ³Arthritis & Rheumatism Associates, PC, Alexandria, VA, ⁴Association of Women in Rheumatology, New York, NY, ⁵Washington DC VA Medical Center, Washington, DC
Background/Purpose: In 2015, the American College of Rheumatology (ACR) began Advocacy 101 in person-education for Fellows in Training (FIT) and physicians to encourage participation in…
Abstract Number: 0643 • ACR Convergence 2020
Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
Carlos González¹, Luis Menchén¹, Indalecio Monteagudo¹, Ofelia Baniandrés², Juan Carlos Nieto Gonzalez¹, Ignacio Marín-Jiménez¹, Ana Herranz-Alonso¹, Carmen Lobo-Rodríguez¹, Amparo López-Esteban¹, Ana López¹, Arantza Ais-Larisgoitia¹, Esther Chamorro de Vega¹, Paloma Morales de los Ríos¹, Maria Jesús Lizcano¹, Jose Maria Alvaro-Gracia¹ and Sonia García de San-José¹, ¹CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
Background/Purpose: To analyze the risk of admission for COVID19 infection and outcome of patients treated with b/tsDMARD from our center, to compare with all patients…
Abstract Number: 0819 • ACR Convergence 2020
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Joseph Alanaeme¹, Sujith Sarvesh¹, Jeffrey R Curtis² and Huifeng Yun², ¹University of Alabama at Birmingham, BIrmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…
Abstract Number: 0898 • ACR Convergence 2020
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
Julie Birt¹, Michael Grabner², Keith Isenberg³, Theresa Hunter⁴, Chia-Chen Teng², Mingyang Shan¹, Jeffrey Lisse¹, Jianmin Wu¹, Kirstin Griffing¹ and Jeffrey R Curtis⁵, ¹Eli Lilly and Company, Indianapolis, IN, ²Healthcore, Inc, Wilmington, DE, ³Anthem, Inc, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year associated with advanced therapy (AT) initiation among…
Abstract Number: 1210 • ACR Convergence 2020
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Clifton Bingham III¹, Shelly Kafka², Shawn Black², Stephen Xu³, Wayne Langholff⁴ and Jeffrey R Curtis⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative & Pragmatic Study of Golimumab [GLM] Intravenous [IV] vs Infliximab [IFX] in RA) is a Phase 4 study designed to provide a…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Dilli Poudel¹, Ted Mikuls², Michael George¹, Bryant England², Grant Cannon³, Brian Sauer⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, ⁴University of Utah, Omaha, NE
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…
Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne² and Peter A. Merkel³, ¹University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ³Division of Rheumatology University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…
Abstract Number: 0222 • ACR Convergence 2020
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
Diederik De Cock¹, Patrick Durez², Dirk Elewaut³, Bernard Lauwerys⁴, Rene Westhovens⁵ and Patrick Verschueren⁶, ¹KU Leuven, Leuven, Belgium, ²Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ³Ghent University and VIB, Heusden, Belgium, ⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁵University Hospitals Leuven, Belgium, Leuven, Belgium, ⁶University Hospital Leuven, Leuven, Belgium
Background/Purpose: The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining the collection of data from all Belgian patients with Rheumatoid…
Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Uta Kiltz¹, Jan Brandt-Jürgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ³Ambulantes Rheumazentrum, Erfurt, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…
Abstract Number: 0505 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
Xenofon Baraliakos¹, Laure Gossec², Effie Pournara³, Slawomir Jeka⁴, Ricardo Blanco⁵, Salvatore D'Angelo⁶, Georg Schett⁷, Barbara Schulz³, Michael Rissler³, Dermot Whyms⁸, Chiara Perella³ and Laura Coates⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy, ⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁸Novartis Ireland Limited, Dublin, Ireland, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…
Abstract Number: 0713 • ACR Convergence 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Daniel J Lovell¹, Hermine Brunner², Nikolay Tzaribachev³, Esi Morgan², Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Ilonka Orban¹⁵, Jason Dare¹⁶, Ivan Foeldvari¹⁷, Pierre Quartier¹⁸, Alyssa Dominique¹⁹, Tzuyung Douglas Kou¹⁹, Robert Wong¹⁹, Alberto Martini²⁰ and Nicolino Ruperto²⁰, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁶University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁷Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁸Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁹Bristol-Myers Squibb Company, Princeton, NJ, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
Abstract Number: 0821 • ACR Convergence 2020
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Vijaya Rivera¹, Sandra Sicsik Ayala¹, David Vega Morales², Fedra Irazoque-Palazuelos³, Dafhne Miranda Hernández¹, Julio Casasola Vargas¹, Sandra Carrillo Vázquez¹, Angélica Peña Ayala¹, Angel Castillo Ortiz¹, Omar Muñoz Monroy¹, Sergio Durán Barragán¹, Aleni Paz Viscarra¹, Estefanía Torres Valdez¹, Daniel Xibille Friedmann¹, Erick A Zamora Tehozol⁴, Luis Valdés Corona¹, Azucena Ramos Sánchez¹, Natalia Santana Portillo¹, Francisco Guerrero Díaz¹, Miguel Vazquez Zaragoza¹, Claudia Zepeda Moreno¹, Kitzia Alvarado Sánchez¹, Melanea Rivera Valencia¹, Cesar Pacheco Tena⁵ and Deshire Alpizar-Rodriguez⁶, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Universidad Autónoma de Nuevo León, Garcia, Mexico, ³Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ⁴Centro Médico Pensiones, Merida, Yucatan, Mexico, ⁵Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁶Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and is more frequent and severe in women than in men. Symptom severity, disease progression,…
Abstract Number: 0899 • ACR Convergence 2020
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
Denis Poddubnyy¹, Effie Pournara², Agnieszka Zielinska³, Asta Baranauskaite⁴, Alejandro Muñoz Jiménez⁵, Sanchayita Sadhu⁶, Barbara Schulz², Michael Rissler², Chiara Perella² and Helena Marzo-Ortega⁷, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Medycyna Kliniczna, Warszawa, Poland, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ⁶Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁷The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.